-
UK Pharmacogenetics & Stratified Medicine Network
We are dedicated to developing collaborative partnerships
between healthcare professionals, academic researchers,
industry partners, regulatory bodies and patients
to synergise research into stratified medicine across the UK
and support its adoption into the clinic.
-
-
Funding
Funding opportunities for research into stratified medicine27 Sep 2017
MRC/AstraZeneca Centre for Lead Discovery27 Sep 2017
MRC/UCB Antibody Discovery Initiative11 Oct 2017
Digital Health Technology Catalyst 2017 Round 111 Oct 2017
New and novel healthcare solutions: apply for innovation funding13 Oct 2017
NICE AdviSeME Prize25 Oct 2017
Precision medicine: impacting through innovative technology27 Oct 2017
SBRI funding competition: Exploiting data to improve cancer care07 Nov 2017
MRC Confidence in Concept scheme 201715 Jan 2018
JLABS @ NYC QuickFire Challenge -
-
Latest News
Upcoming Events & Funding Deadlines
The network is made up of experts from academia, healthcare sector, industry, regulatory bodies and patient groups
and aims to develop collaborations between these different sectors to advance the adoption of stratified medicine into the clinic.
If you need to find a research partner, simply click to download the collaboration form, provide information on your current project(s)
and we will advertise your request to help put you in touch with the relevant individual or institution.
Connecting with the right partner will enable you to push your research to the next level.
What is Pharmacogenetics?
What is Stratified Medicine?
Stratified medicine (also described as personalised, precision, or P4 Predictive, Preventive, Personalized and Participatory medicine) uses technical advances in genetic sequencing techniques, and bespoke diagnostic tests, to prescribe the drug that is most likely to have a positive therapeutic effect, at the optimum dose and in the right combination with other medication, to patients at the start of their treatment. Thus patients have their treatment based on their genetic profile, molecular basis of their disease, risk of disease, or response to a particular drug therapy, rather than the signs or symptoms of their disease.
Traditionally patients have been prescribed their medication based on the signs and symptoms of their disease. If a treatment is not successful patients have to be prescribed an alternative medication.
Academic and clinical research has revealed that most diseases have multiple subtypes that require different treatment approaches. Pharmacogenetic data and bespoke diagnostic tests enable clinicians to identify the subcategory of disease and offer patients the most effective treatments from the outset of their treatment.